Asthma Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-Severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy
Verified date | May 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events. Secondary Objectives: To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340 and dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1). To evaluate the effects of coadministration of SAR440340 and dupilumab, compared with SAR440340 and compared with dupilumab, on FEV1. To assess safety and tolerability of SAR440340 alone and in coadministration with dupilumab.
Status | Completed |
Enrollment | 296 |
Est. completion date | August 7, 2019 |
Est. primary completion date | March 21, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion criteria : - Adult participants with a physician diagnosis of asthma for at least 12 months based on the Global Initiative for Asthma (GINA) 2017 Guidelines. - Participants with existing treatment with medium to high dose ICS (greater than or equal to [>=] 250 microgram (mcg) of fluticasone propionate twice a day (BID) or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or clinically comparable) in combination with a LABA as second controller for at least 3 months with a stable dose >=1 month prior to Visit 1. - Participants with pre-bronchodilator FEV1 greater than (>) 40 percent (%) of predicted normal at Visit 1/Screening. Pre-bronchodilator FEV1 >=50% but less than or equal to (<=) 85% of predicted normal at Visit 2/Baseline. - Participants with reversibility of at least 12% and 200 milliliters (mL) in FEV1 after administration of 2 to 4 puffs (200-400 microgram [µg]) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criteria within 12 months prior to Visit 1 or documented positive response to methacholine challenge (a decrease in FEV by 20% [PC20] of less than [<] 8 milligram per milliliter [mg/mL]) within 12 months prior to Visit 1/Screening is considered acceptable to meet this inclusion criterion. - Participants had experienced, within 1 year prior to Visit 1, any of the following events at least once: - Treatment with a systemic steroid (oral or parenteral) for worsening asthma. - Hospitalization or emergency medical care visit for worsening asthma. - Signed written informed consent. Exclusion criteria: - Participants <18 years or >70 years of age (i.e., have reached the age of 71 at the screening visit). - Participants with body mass index (BMI) <16. - Chronic lung disease (for example, chronic obstructive pulmonary disease [COPD], or idiopathic pulmonary fibrosis [IPF]), which might impair lung function. - History of life threatening asthma (i.e., severe exacerbation that required intubation). - Co-morbid disease that might interfere with the evaluation of investigational medicinal product (IMP). - Participants with any of the following events within the 4 weeks prior to their Screening Visit 1: - Treatment with 1 or more systemic (oral and/or parenteral) steroid bursts for worsening asthma; - Hospitalization or emergency medical care visit for worsening asthma. - Asthma Control Questionnaire 5-question version (ACQ-5) score <1.25 or >3.0 at Visit 2/randomization. During the screening period, an ACQ-5 of up to <=4 was acceptable. - Anti-immunoglobulin E (IgE) therapy (e.g., omalizumab [Xolair®]) within 130 days prior to Visit 1 or any other biologic therapy (including anti interleukin-5 [anti-IL5] monoclonal antibodies [mAb]) or systemic immunosuppressant (e.g., methotrexate) to treat inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever was longer. - Participants with a history of a systemic hypersensitivity reaction to a biologic drug. - Participants on or initiation of bronchial thermoplasty within 2 years prior to Visit 1 or plan to begin therapy during the screening period or the randomized treatment period. - Current smoker or cessation of smoking within the 6 months prior to Visit 1. - Previous smoker with a smoking history >10 pack-years. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Argentina | Investigational Site Number 0320001 | Buenos Aires | |
Argentina | Investigational Site Number 0320002 | Caba | |
Argentina | Investigational Site Number 0320003 | Caba | |
Argentina | Investigational Site Number 0320004 | Caba | |
Argentina | Investigational Site Number 0320005 | Mendoza | |
Chile | Investigational Site Number 1520002 | Quillota | |
Chile | Investigational Site Number 1520001 | Santiago | |
Chile | Investigational Site Number 1520004 | Santiago | |
Chile | Investigational Site Number 1520007 | Santiago | |
Chile | Investigational Site Number 1520008 | Santiago | |
Chile | Investigational Site Number 1520009 | Santiago | |
Chile | Investigational Site Number 1520005 | Talca | |
Chile | Investigational Site Number 1520003 | Viña Del Mar | |
Mexico | Investigational Site Number 4840005 | Chihuahua | |
Mexico | Investigational Site Number 4840004 | Durango | |
Mexico | Investigational Site Number 4840002 | Guadalajara | |
Mexico | Investigational Site Number 4840001 | Monterrey | |
Mexico | Investigational Site Number 4840006 | Monterrey | |
Mexico | Investigational Site Number 4840003 | Veracruz | |
Poland | Investigational Site Number 6160001 | Bialystok | |
Poland | Investigational Site Number 6160008 | Bialystok | |
Poland | Investigational Site Number 6160005 | Bydgoszcz | |
Poland | Investigational Site Number 6160007 | Krakow | |
Poland | Investigational Site Number 6160002 | Poznan | |
Poland | Investigational Site Number 6160006 | Poznan | |
Poland | Investigational Site Number 6160003 | Znin | |
Russian Federation | Investigational Site Number 6430001 | Moscow | |
Russian Federation | Investigational Site Number 6430003 | Moscow | |
Russian Federation | Investigational Site Number 6430005 | Moscow | |
Russian Federation | Investigational Site Number 6430008 | Ryazan | |
Russian Federation | Investigational Site Number 6430006 | Saint-Petersburg | |
Russian Federation | Investigational Site Number 6430010 | Saint-Petersburg | |
Russian Federation | Investigational Site Number 6430007 | St-Petersburg | |
Russian Federation | Investigational Site Number 6430009 | Stavropol | |
Russian Federation | Investigational Site Number 6430004 | Ulyanovsk | |
Turkey | Investigational Site Number 7920004 | Ankara | |
Turkey | Investigational Site Number 7920003 | Bursa | |
Turkey | Investigational Site Number 7920001 | Istanbul | |
Turkey | Investigational Site Number 7920006 | Izmir | |
Turkey | Investigational Site Number 7920007 | Izmir | |
Turkey | Investigational Site Number 7920008 | Kirikkale | |
Turkey | Investigational Site Number 7920002 | Mersin | |
Turkey | Investigational Site Number 7920009 | Rize | |
Ukraine | Investigational Site Number 8040008 | Chernivtsi | |
Ukraine | Investigational Site Number 8040012 | Ivano-Frankivsk | |
Ukraine | Investigational Site Number 8040002 | Kharkiv | |
Ukraine | Investigational Site Number 8040009 | Kharkiv | |
Ukraine | Investigational Site Number 8040011 | Kharkiv | |
Ukraine | Investigational Site Number 8040001 | Kyiv | |
Ukraine | Investigational Site Number 8040007 | Kyiv | |
Ukraine | Investigational Site Number 8040006 | Odesa | |
Ukraine | Investigational Site Number 8040003 | Ternopil | |
Ukraine | Investigational Site Number 8040005 | Vinnytsya | |
United States | Investigational Site Number 8400021 | Ann Arbor | Michigan |
United States | Investigational Site Number 8400026 | Birmingham | Alabama |
United States | Investigational Site Number 8400016 | Colorado Springs | Colorado |
United States | Investigational Site Number 8400010 | Dallas | Texas |
United States | Investigational Site Number 8400023 | Dallas | Texas |
United States | Investigational Site Number 8400025 | Edmond | Oklahoma |
United States | Investigational Site Number 8400004 | Long Beach | California |
United States | Investigational Site Number 8400020 | Los Angeles | California |
United States | Investigational Site Number 8400011 | Medford | Oregon |
United States | Investigational Site Number 8400014 | Milwaukee | Wisconsin |
United States | Investigational Site Number 8400022 | Minneapolis | Minnesota |
United States | Investigational Site Number 8400008 | Murray | Utah |
United States | Investigational Site Number 8400007 | Papillion | Nebraska |
United States | Investigational Site Number 8400006 | Plano | Texas |
United States | Investigational Site Number 8400024 | Portland | Oregon |
United States | Investigational Site Number 8400001 | Rolling Hills Estates | California |
United States | Investigational Site Number 8400013 | San Jose | California |
United States | Investigational Site Number 8400009 | Stockton | California |
Lead Sponsor | Collaborator |
---|---|
Sanofi | Regeneron Pharmaceuticals |
United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Loss of Asthma Control | An LOAC event during the 12-week treatment period was a deterioration of asthma defined as any of the following: a) 30 percent (%) or greater reduction from baseline in morning peak expiratory flow (PEF) on 2 consecutive days; b) greater than or equal to (>=) 6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; c) increase in inhaled corticosteroid (ICS) >=4 times the last prescribed ICS dose (or >=50% of the prescribed ICS dose at Baseline if background therapy withdrawal completed); d) required use of systemic (oral and/or parenteral) steroid treatment; e) required hospitalization or emergency room visit. | From Baseline up to Week 12 | |
Secondary | Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Pre-bronchodilator FEV1 refers to the spirometry performed after a wash period of bronchodilators (i.e., not earlier than 6 hours) after the last dose of albuterol/salbutamol or levalbuterol/levosalbutamol from a primed meter dose inhaler and withholding the last dose of long-acting ß2 adrenergic agonist (LABA) for at least 12 hours, and prior to administration of study drug. | Baseline, Week 12 | |
Secondary | Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 refers to the spirometry performed within 30 minutes after administration of bronchodilator. | Baseline, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|